Antibodies

12 Mar 2020 Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279
12 Mar 2020 Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
11 Mar 2020 Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing
11 Mar 2020 Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs
11 Mar 2020 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib
11 Mar 2020 Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
10 Mar 2020 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
10 Mar 2020 First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors
10 Mar 2020 Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
09 Mar 2020 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
09 Mar 2020 Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma
09 Mar 2020 New report with sales data for recombinant therapeutic antibodies and proteins shows continued success of innovative antibodies
09 Mar 2020 CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)
08 Mar 2020 Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer
04 Mar 2020 Amunix Raises $73 Million in Series A Financing Led by Omega Funds
04 Mar 2020 Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
03 Mar 2020 FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
02 Mar 2020 ImmunoPrecise Announces Artificial Intelligence Collaboration with EVQLV to Accelerate Vaccine and Antibody Discovery for SARS-CoV-2 Coronavirus
02 Mar 2020 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
02 Mar 2020 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
02 Mar 2020 FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
29 Feb 2020 Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
29 Feb 2020 Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
27 Feb 2020 iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
27 Feb 2020 Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top